Back to news

Arrowhead Pharmaceuticals Slides as Investors Reassess Recent ARO-DIMER-PA Data

Investivoq PriceTracker

Arrowhead Pharmaceuticals (ARWR) is down 7.3% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver appears to be a continued sell-the-news reaction to Arrowhead’s September 15, 2026 interim ARO-DIMER-PA data release rather than a fresh negative corporate announcement. While the study showed strong early biomarker reductions, investors may be reassessing how much of that promise is already reflected in the stock and how long it could take for those results to translate into later-stage clinical and commercial value.

Details:

  • On September 15, Arrowhead announced interim Phase 1/2a topline data for ARO-DIMER-PA, including mean maximal single-dose reductions of 72% in PCSK9 and 88% in APOC3, along with favorable changes in LDL-C, triglycerides, non-HDL cholesterol, and ApoB.
  • Despite those encouraging efficacy signals, the stock dropped sharply on September 15 and remained volatile afterward, suggesting the market did not treat the update as an unambiguously positive catalyst.
  • Arrowhead’s recent investor materials show no obvious new negative press release between that data update and September 23, which makes a delayed sentiment reset or profit-taking a plausible explanation for today’s weakness.
  • The company’s August 4 quarterly update also showed heavy spending and a sizable quarterly net loss, which can amplify downside moves in development-driven biotech names when enthusiasm cools.

    • Sources:

    Arrowhead Pharmaceuticals ([arrowheadpharma.gcs-web.com](https://arrowheadpharma.gcs-web.com/news-releases/news-release-details/arrowhead-pharmaceuticals-announces-interim-topline-clinical)), Yahoo Finance ([finance.yahoo.com](https://finance.yahoo.com/quote/ARWR/?utm_source=openai)), MarketBeat ([marketbeat.com](https://www.marketbeat.com/stocks/NASDAQ/ARWR/chart/?utm_source=openai))

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $ARWR Insider Trading Activity

    ARWR Insider Trades

    $ARWR insiders have traded $ARWR stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.

    Here’s a breakdown of recent trading of $ARWR stock by insiders over the last 6 months:

    • MICHAEL S PERRY sold 11,600 shares for an estimated $1,012,680
    • DANIEL JOSEPH APEL (Chief Financial Officer) has made 0 purchases and 3 sales selling 13,095 shares for an estimated $934,285.
    • JAMES C HAMILTON (Chief Medical Officer) sold 10,000 shares for an estimated $750,000
    • HONGBO LU sold 2,970 shares for an estimated $228,333
    • ADEOYE Y OLUKOTUN sold 2,000 shares for an estimated $173,920

    To track insider transactions, check out Investivoq's insider trading dashboard. You can access data on insider stock transactions through the Investivoq API insider transaction endpoint.

    EARLY ACCESS
    Receive ARWR Data Alerts
    Real-time alerts on filings, insider trades, and market signals — before everyone else.
    Get Alerts →

    $ARWR Hedge Fund Activity

    We have seen 289 institutional investors add shares of $ARWR stock to their portfolio, and 238 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    • BLACKROCK, INC. removed 3,330,966 shares (-18.3%) from their portfolio in Q2 2026, for an estimated $271,507,038
    • SLATE PATH CAPITAL LP removed 2,523,500 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $158,223,450
    • NORGES BANK added 2,192,072 shares (+128.6%) to their portfolio in Q2 2026, for an estimated $178,675,788
    • FIRST TRUST ADVISORS LP added 1,203,770 shares (+807.1%) to their portfolio in Q2 2026, for an estimated $98,119,292
    • HOLOCENE ADVISORS, LP added 1,106,177 shares (+inf%) to their portfolio in Q2 2026, for an estimated $90,164,487
    • SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 923,927 shares (+inf%) to their portfolio in Q2 2026, for an estimated $75,309,289
    • FMR LLC added 773,152 shares (+10.6%) to their portfolio in Q2 2026, for an estimated $63,019,619

    To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

    $ARWR Price Targets

    Multiple analysts have issued price targets for $ARWR recently. We have seen 7 analysts offer price targets for $ARWR in the last 6 months, with a median target of $88.0.

    Here are some recent targets:

    • Patrick R. Trucchio from HC Wainwright & Co. set a target price of $100.0 on 07/01/2026
    • Keay Nakae from Chardan Capital set a target price of $90.0 on 06/30/2026
    • Mani Foroohar from Leerink Partners set a target price of $72.0 on 06/17/2026
    • William Pickering from Bernstein set a target price of $46.0 on 05/13/2026
    • Luca Issi from RBC Capital set a target price of $87.0 on 05/08/2026
    • Brian Cheng from JP Morgan set a target price of $88.0 on 05/01/2026
    • Michael Ulz from Morgan Stanley set a target price of $100.0 on 04/21/2026

    This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.